FNA - רווח לפני ריבית, מסים ופחת Paragon 28, Inc.

Intense competition with medtech giants is putting pressure on quotes, as reflected in the EBITDA trend, where the latest value is recorded as . Rising demand driven by an aging population and a unique product line support the business. High margins and the popularity of the Apex and Silverback lines ensure that Paragon 28, Inc. (FNA) maintains sustainable growth within the outpatient foot surgery segment.

To select assets with a high margin of fundamental strength, it is critical to analyze operating cash flow before interest and taxes. This operating financial result measures the real ability of Paragon 28, Inc. (FNA) to generate cash, which, coupled with the expansion of the implant product line and surgeon loyalty, allows the company to offset past accounting errors and confirms the stability of the business's margins.